Prediction of Human Pharmacokinetics of Therapeutic Monoclonal Antibodies from Simple Allometry of Monkey Data

被引:67
作者
Oitate, Masataka [1 ]
Masubuchi, Noriko [1 ]
Ito, Takashi [1 ]
Yabe, Yoshiyuki [1 ]
Karibe, Tsuyoshi [1 ]
Aoki, Takanori [1 ]
Murayama, Nobuyuki [1 ]
Kurihara, Atsushi [1 ]
Okudaira, Noriko [1 ]
Izumi, Takashi [1 ]
机构
[1] Daiichi Sankyo Co Ltd, Drug Metab & Pharmacokinet Res Labs, Shinagawa Ku, Tokyo 1408710, Japan
关键词
monoclonal antibody; allometric scaling; prediction; clearance; distribution volume; pharmacokinetics; HUMAN DRUG CLEARANCE; DIMERIZATION INHIBITOR; PERTUZUMAB;
D O I
10.2133/dmpk.DMPK-11-RG-011
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Interspecies allometric scaling is a useful tool for calculating human pharmacokinetic (PK) parameters from data in animals. In this study, in order to determine the scaling exponent in a simple allometric equation that can predict human clearance (CL) and distribution volume at steady state (Vss) of monoclonal antibodies (mAbs) from monkey data alone, PK data of 24 mAbs were collected and analyzed according to the types of targeted antigens (soluble or membrane-bound antigens). Based on the observed PK data in humans (at clinical doses) and monkeys (at >1 mg/kg), where the PK is expected to be linear, the mean scaling exponents in the allometric equation for CL and Vss, respectively, against body weight were calculated to be 0.79 and 1.12 [95% confidence intervals (CIs): 0.69-0.89 and 0.96-1.28] for soluble antigens, and 0.96 and 1.00 (95% CIs: 0.83-1.09 and 0.87-1.13) for membrane-bound antigens. Using these exponents and monkey PK data (at >1 mg/kg) alone, both human CL and Vss of mAbs can be predicted with reasonable accuracy, i.e., within 2-fold of the observed values. Compared with traditional allometric scaling using PK data from three or more preclinical species, this approach is simple, quick, resource-saving, and useful in drug discovery and development.
引用
收藏
页码:423 / 430
页数:8
相关论文
共 32 条
[1]   Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab [J].
Adams, CW ;
Allison, DE ;
Flagella, K ;
Presta, L ;
Clarke, J ;
Dybdal, N ;
McKeever, K ;
Sliwkowski, MX .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2006, 55 (06) :717-727
[2]   Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer [J].
Agus, DB ;
Gordon, MS ;
Taylor, C ;
Natale, RB ;
Karlan, B ;
Mendelson, DS ;
Press, MF ;
Allison, DE ;
Sliwkowski, MX ;
Lieberman, G ;
Kelsey, SM ;
Fyfe, G .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (11) :2534-2543
[3]   INTERSPECIES PHARMACOKINETIC SCALING AND THE EVOLUTIONARY-COMPARATIVE PARADIGM [J].
BOXENBAUM, H .
DRUG METABOLISM REVIEWS, 1984, 15 (5-6) :1071-1121
[4]   INTERSPECIES SCALING, ALLOMETRY, PHYSIOLOGICAL TIME, AND THE GROUND PLAN OF PHARMACOKINETICS [J].
BOXENBAUM, H .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1982, 10 (02) :201-225
[5]  
Boxenbaum H, 1990, Adv Drug Res, V19, P139
[6]  
Chappell W., 1991, ADV DRUG RES, P1
[7]   Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data What have we learned? [J].
Deng, Rong ;
Iyer, Suhasini ;
Theil, Frank-Peter ;
Mortensen, Deborah L. ;
Fielder, Paul J. ;
Prabhu, Saileta .
MABS, 2011, 3 (01) :61-66
[8]   Pharmacokinetics of Humanized Monoclonal Anti-Tumor Necrosis Factor-α Antibody and Its Neonatal Fc Receptor Variants in Mice and Cynomolgus Monkeys [J].
Deng, Rong ;
Loyet, Kelly M. ;
Lien, Samantha ;
Iyer, Suhasini ;
DeForge, Laura E. ;
Theil, Frank-Peter ;
Lowman, Henry B. ;
Fielder, Paul J. ;
Prabhu, Saileta .
DRUG METABOLISM AND DISPOSITION, 2010, 38 (04) :600-605
[9]  
FDA, UST STEL DRUG APPR P
[10]  
FDA, DACL ZEN DRUG APPR P